



**PIPER RUDNICK LLP**  
1200 NINETEENTH STREET, NW  
WASHINGTON, DC 20036-2412  
TELEPHONE: 202-861-3900  
FACSIMILE: 202-223-2085

RECEIVED  
JUN 25 2002  
TECH CENTER 1600/2900  
#14  
6/28/02

DOCKET NO.: 9491-043-27 DIV

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Re: Serial No.: 09/610,152  
Applicant(s): Napoleone FERRERA et al.  
Filing Date: July 5, 2000  
For: IMPROVED ANGIOGENESIS USING HEPATOCYTE GROWTH  
FACTOR  
Group Art Unit: 1651  
Examiner: J. Weber

SIR:

Attached hereto for filing are the following papers:

**AMENDMENT AFTER FINAL**

Our check in the amount of \$ 0 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

PIPER RUDNICK LLP ,

Steven B. Kelber  
Attorney of Record  
Registration No.: 30,073

Patrick R. Delaney  
Registration No.: 45,338

RECEIVED

JUN 25 2002

TECH CENTER 1600/2900



Docket No. 9491-043-27 DIV

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: NAPOLEONE FERRARA, ET AL. GAU: 1651  
SERIAL NO: 09/610,152 EXAMINER: WEBER, J.  
FILING DATE: JULY 5, 2000  
FOR: IMPROVED ANGIOGENESIS USING HEPATOCYTE GROWTH FACTOR

**AMENDMENT AFTER FINAL**

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

This Amendment is submitted in answer to the Office Action dated April 5, 2002, which set a three month period for response. Thus, this Amendment is considered timely filed on or before July 5, 2002.

**IN THE CLAIMS**

Upon entry of this Amendment claims 8-16 will remain pending.

Please add the following new Claim.

--16. (New) The pharmaceutical composition of Claim 11, wherein said carrier comprises bovine serum albumin, polyoxyethylenesorbitan monolaurate, thimersol, and phosphate buffered saline.- -

**REMARKS**

Applicants respectfully request a full and fair response to the points raised in the following argument. Applicants take exception to the mere recitation of sections from the MPEP in the previous Office Action as failing to further prosecution and not adequately developing the record should this case need be taken up on appeal.